Wolfgang Fischl is Co-founder and CEO of YGION Biomedical, established in 2022, where he leads the development and production of personalized cancer vaccines. He previously held key roles in research and product development at various biotech companies in the area of anti-infectives and metabolic disorders. He earned a Ph.D. in Biology from the University of Heidelberg and holds a Molecular Biology diploma from the University of Vienna. Wolfgang is driven by a passion for advancing personalized medicine and committed to developing innovative therapies that improve patient outcomes and push the boundaries of cancer treatment.